Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.320
-0.010 (-0.75%)
At close: Feb 27, 2026, 4:00 PM EST
1.340
+0.020 (1.52%)
After-hours: Feb 27, 2026, 7:39 PM EST
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,564,432
Market Cap
6.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Dec 31, 2023 | 10 | 4 | 66.67% |
| Dec 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 28 |
| Theriva Biologics | 22 |
| VivoSim Labs | 14 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 9 |
| Aprea Therapeutics | 8 |
| Immuron | 7 |
| Can-Fite BioPharma | 5 |
REVB News
- 2 days ago - Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 - Accesswire
- 4 weeks ago - Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 - Accesswire
- 5 weeks ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Accesswire
- 5 weeks ago - Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - Accesswire
- 6 weeks ago - Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - Accesswire
- 6 weeks ago - Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Accesswire
- 7 weeks ago - Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - Accesswire
- 3 months ago - Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting - Accesswire